Company Analysis
Sign in

Evaxion A/S (EVAX)

Nasdaq: EVAX · Biological Products, (No Diagnostic Substances) · filing with the SEC since 2020
Full chart Alerts Compare
Grade5.1
◀ Past 5.3● Present 4.3▶ Future 5.6
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

13 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Evaxion A/S’s names, not what it holds today.

Patents granted
13
13 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 2 in 2024 and 2 in 2023
Applications published
23
5 of them in 2025
Names they are printed under
2
a former name
By yearGrantedApplications published
'16'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals6
Biotechnology3
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Evaxion Biotech A/S a former name
named as the applicant on its applications, in DK
0 granted
22 published
Evaxion Biotech A/S a former name
DK, as the owner printed on each patent
13 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Feb 18, 202512,226,469Proteins and nucleic acids useful in vaccines targeting Klebsiella pneumoniaeBiotechnologyEvaxion Biotech A/S
Jan 28, 202512,209,110Chimeric proteins for inducing immunity towards infection with S. aureusPharmaceuticalsEvaxion Biotech A/S
Jun 11, 202412,006,342Proteins and nucleic acids useful in vaccines targeting Pseudomonas aeruginosaPharmaceuticalsEvaxion Biotech A/S
Jan 2, 202411,857,615Peptides derived from Acinetobacter baumannii and their use in vaccinationPharmaceuticalsEvaxion Biotech A/S
Nov 7, 202311,807,669Proteins and nucleic acids useful in vaccines targeting Staphylococcus aureusBiotechnologyEvaxion Biotech A/S
Aug 8, 202311,718,648Vaccines targeting Pseudomonas aeruginosaBiotechnologyEvaxion Biotech A/S
Aug 16, 202211,414,464Chimeric proteins for inducing immunity towards infection with S. aureusPharmaceuticalsEvaxion Biotech A/S
Jul 6, 202111,052,145Proteins and nucleic acids useful in vaccines targeting Staphylococcus aureusPharmaceuticalsEvaxion Biotech A/S
Mar 16, 202110,946,084Proteins and nucleic acids useful in vaccines targeting Staphylococcus aureusPharmaceuticalsEvaxion Biotech A/S
Dec 1, 202010,849,968Proteins and nucleic acids useful in vaccines targeting Klebsiella pneumoniaeBiotechnologyEvaxion Biotech A/S
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 2, 20252025/0304626Vaccination targeting intracellular pathogensPharmaceuticalsEvaxion Biotech A/S
Sep 18, 20252025/0288657Staphylococcal protein variants and truncatesPharmaceuticalsEvaxion Biotech A/S
Jun 26, 20252025/0205325Proteins and nucleic acids useful in vaccines targeting Klebsiella pneumoniaeBiotechnologyEvaxion Biotech A/S
Mar 20, 20252025/0095818Method for predicting response to cancer immunotherapyMedical technologyEvaxion Biotech A/S
Feb 13, 20252025/0054576Personalized cancer therapy targeting normally non-expressed sequencesComputer technologyEvaxion Biotech A/S
Dec 26, 20242024/0424079Vaccines targeting Neisseria gonorrhoeaePharmaceuticalsEvaxion Biotech A/S
Sep 26, 20242024/0317817Proteins and nucleic acids useful in vaccines targeting Pseudomonas aeruginosaPharmaceuticalsEvaxion Biotech A/S
Jul 11, 20242024/0228554PROTEINS AND NUCLEIC ACIDS USEFUL IN VACCINES TARGETING STAPHYLOCOCCUS AUREUSBiotechnologyEvaxion Biotech A/S
Jul 11, 20242024/0226263PEPTIDES DERIVED FROM ACINETOBACTER BAUMANNII AND THEIR USE IN VACCINATIONPharmaceuticalsEvaxion Biotech A/S
Apr 25, 20242024/0132552PROTEINS AND NUCLEIC ACIDS USEFUL IN VACCINES TARGETING STAPHYLOCOCCUS AUREUSBiotechnologyEvaxion Biotech A/S
What it applied for, 2024 to 2025: Pharmaceuticals 5 · Biotechnology 4 · Computer technology 1 · Medical technology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton EVAX · research, not advice